TARDBP and amyotrophic lateral sclerosis: For example, in a recent study by Yang etal., they designed an aggregation-resistant CTD phosphomimetic mutant(S333D/S342D) to identify small molecules that stabilize TDP-43’snative state in a cell-free platform. Theversatility of our counter-screening strategy allows exploration ofdomain specific TDP-43 aggregation dynamics, FTD/ALS-related mutations,and the impact of ALS/FTD-risk factors like neuroinflammation or environmentaltoxins on TDP-43 assemblies.−, , , ,